HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eager For US Rule On Novel OTC Switches? Submit NDAs To Spur FDA Thinking – Gottlieb

Executive Summary

Former FDA Commissioner Scott Gottlieb says OTC drug switch sponsors could expedite introduction of agency’s long-awaited proposed rule on switch NDAs by submitting applications. During CHPA webinar, he said innovation by industry guides agency in rulemaking.

Drug firms eager for a US Food and Drug Administration proposed rule on novel OTC switches could help accelerate its development and publication by submitting switch proposals, says former Commissioner Scott Gottlieb.

“I think the best thing a sophisticated sponsor can do is challenge the system with a well-thought-out application. That then becomes the template for how [policy] gets written,” Gottlieb said during an online presentation for the Consumer Healthcare Product Association on 22 March.

“Creativity is going to come from the sponsors, it’s not going to come from the agency. The agency is going to react from what it’s seeing and write rules around what it is seeing to try to enable useful innovations, said Gottlieb, who was commissioner from May 2017 to April 2019.

The FDA published a draft guidance in July 2018 advising sponsors on options for proposing novel switches, which will feature extra-label components in the information consumers will access about product selection and use. The draft suggested data to include in new drug applications for switches, such as digital content accessed separately from a  product’s Drug Facts label that ensure “appropriate self-selection by consumers, appropriate actual use, or both, to obtain the drug without a prescription.” (Also see "Innovation In OTC Switches Takes Multimedia Approach In US FDA Draft Guidance" - HBW Insight, 17 Jul, 2018.)

The agency said the draft would be followed “in the near future” by rulemaking for approving switches based on the guidance’s recommended approach. Together, the guidance and a rule would supplant the FDA’s existing rules for evaluating switch proposals with a more flexible and comparatively more simple policy.

FDA commissioner Scott Gottlieb former fda commissioner scott gottlieb: "Creativity is going to come from the sponsors, it’s not going to come from the agency."

Gottlieb, discussing industry concerns with CHPA president Scott Melville during the webinar, acknowledged that NDA sponsors are frustrated by the agency’s perceived delay in introducing the rule. Waiting for the FDA, however, may add to the delay, he suggested.

“Sometimes we think we have to wait for FDA to issue a [policy] so we know what the rules of the road have to be and FDA is sitting there saying, ‘let’s see what happens and then we can see what’s working and what’s not. Then we can write the rules of the road,’” Gottlieb said.

Drug firms’ investments in preparing a switch NDA, he added, could become investments in policy, too.

“I would make an investment in trying to bring something forward and develop an innovative set of parameters around that hoping it becomes the policy. I wouldn’t wait for the policy to get written.”

Considering the FDA’s rulemaking history, Gottlieb said when a strong rule is developed, “it’s because the regulator saw something in the market and knew it was a good idea and wanted to facilitate it.”

The draft guidance itself wasn’t quick to surface It was published more than six years after the FDA launched an initiative to facilitate making more drugs available OTC – which it dubbed NSURE, for "nonprescription safe use regulatory extension." (Also see "FDA Aims To “NSURE” Clarity About New Paradigm For OTC Switches" - Pink Sheet, 5 Nov, 2012.)

Monograph Reform Shows FDA Receptive To Innovation

Asked during the call when the rule is likely to be implemented, Gottlieb said, “It’s hard for me to know.”

However, Gottlieb he said OTC monograph reform Congress approved in 2020 is a good sign that the agency is pushing for changes that acknowledge self-care and telehealth are the future of health care. 

He added, though, that marketplace results from monograph reform won’t come soon.

“OTC reform only recently was implemented, the resources haven’t flowed through. So we’re not going to see the payoff right away.”

OTC monograph reform legislation grants the FDA authority to use administrative orders for imposing rules, including setting timelines for agency decisions on industry proposals and a process for firms to appeal proposal rejections. The legislation was based on a proposal the FDA developed in discussions with CHPA staff and other industry stakeholders. (Also see "US Regulatory SUNSET Misses FDA’s OTC Drug Regulations, But Reaches Supplement Rules" - HBW Insight, 11 Jan, 2021.)

Gottlieb was a supporter of OTC monograph reform. He noted during his confirmation hearing in 2017 that he was aware the monograph program was overdue for overhaul when he’d previously worked in multiple executive posts at the agency. (Also see "Gottlieb Recognizes OTC Monograph Woes During Confirmation Hearing" - HBW Insight, 6 Apr, 2017.)

 

Related Content

Topics

UsernamePublicRestriction

Register

RS151136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel